These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 27164508)

  • 21. Effect of achieving sustained virological response before hepatitis C virus-related hepatocellular carcinoma occurrence on survival and recurrence after curative surgical microwave ablation.
    Ryu T; Takami Y; Wada Y; Tateishi M; Matsushima H; Yoshitomi M; Mikagi K; Saitsu H
    Hepatol Int; 2018 Mar; 12(2):149-157. PubMed ID: 29488056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy.
    D'Ambrosio R; Aghemo A; Rumi MG; Primignani M; Dell'Era A; Lampertico P; Donato MF; De Nicola S; Prati GM; de Franchis R; Colombo M
    Antivir Ther; 2011; 16(5):677-84. PubMed ID: 21817189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy.
    Lens S; Rincón D; García-Retortillo M; Albillos A; Calleja JL; Bañares R; Abraldes JG; Bosch J; Sanchez-Tapias JM; Forns X; García-Pagán JC
    Clin Gastroenterol Hepatol; 2015 Oct; 13(10):1846-1853.e1. PubMed ID: 25912838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis.
    Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J
    Liver Int; 2016 Jun; 36(6):817-26. PubMed ID: 26787002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Kawaoka T; Aikata H; Teraoka Y; Inagaki Y; Honda F; Hatooka M; Morio K; Morio R; Kobayashi T; Nagaoki Y; Nakahara T; Hiramatsu A; Tsuge M; Imamura M; Kawakami Y; Chayama K
    Oncology; 2017; 92(6):335-346. PubMed ID: 28245484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis.
    Alonso López S; Manzano ML; Gea F; Gutiérrez ML; Ahumada AM; Devesa MJ; Olveira A; Polo BA; Márquez L; Fernández I; Cobo JCR; Rayón L; Riado D; Izquierdo S; Usón C; Real Y; Rincón D; Fernández-Rodríguez CM; Bañares R
    Hepatology; 2020 Dec; 72(6):1924-1934. PubMed ID: 33022803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis.
    Aleman S; Rahbin N; Weiland O; Davidsdottir L; Hedenstierna M; Rose N; Verbaan H; Stål P; Carlsson T; Norrgren H; Ekbom A; Granath F; Hultcrantz R
    Clin Infect Dis; 2013 Jul; 57(2):230-6. PubMed ID: 23616492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals.
    Lleo A; Aglitti A; Aghemo A; Maisonneuve P; Bruno S; Persico M;
    Dig Liver Dis; 2019 Feb; 51(2):310-317. PubMed ID: 30473220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C.
    Jung CH; Um SH; Kim TH; Yim SY; Suh SJ; Yim HJ; Seo YS; Choi HS; Chun HJ
    Gut Liver; 2016 Sep; 10(5):808-17. PubMed ID: 27114417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varices.
    Brzdęk M; Zarębska-Michaluk D; Kukla M; Janocha-Litwin J; Dybowska D; Janczewska E; Lorenc B; Berak H; Mazur W; Tudrujek-Zdunek M; Klapaczyński J; Piekarska A; Sitko M; Laurans Ł; Parfieniuk-Kowerda A; Flisiak R
    Pharmacol Rep; 2024 Oct; 76(5):1114-1129. PubMed ID: 39162985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liver Pathologic Changes After Direct-Acting Antiviral Agent Therapy and Sustained Virologic Response in the Setting of Chronic Hepatitis C Virus Infection.
    Celli R; Saffo S; Kamili S; Wiese N; Hayden T; Taddei T; Jain D
    Arch Pathol Lab Med; 2021 Apr; 145(4):419-427. PubMed ID: 32810870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.
    Pons M; Rodríguez-Tajes S; Esteban JI; Mariño Z; Vargas V; Lens S; Buti M; Augustin S; Forns X; Mínguez B; Genescà J
    J Hepatol; 2020 Mar; 72(3):472-480. PubMed ID: 31629779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C.
    Bruix J; Poynard T; Colombo M; Schiff E; Burak K; Heathcote EJ; Berg T; Poo JL; Mello CB; Guenther R; Niederau C; Terg R; Bedossa P; Boparai N; Griffel LH; Burroughs M; Brass CA; Albrecht JK;
    Gastroenterology; 2011 Jun; 140(7):1990-9. PubMed ID: 21419770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection.
    Matsuura K; Sawai H; Ikeo K; Ogawa S; Iio E; Isogawa M; Shimada N; Komori A; Toyoda H; Kumada T; Namisaki T; Yoshiji H; Sakamoto N; Nakagawa M; Asahina Y; Kurosaki M; Izumi N; Enomoto N; Kusakabe A; Kajiwara E; Itoh Y; Ide T; Tamori A; Matsubara M; Kawada N; Shirabe K; Tomita E; Honda M; Kaneko S; Nishina S; Suetsugu A; Hiasa Y; Watanabe H; Genda T; Sakaida I; Nishiguchi S; Takaguchi K; Tanaka E; Sugihara J; Shimada M; Kondo Y; Kawai Y; Kojima K; Nagasaki M; Tokunaga K; Tanaka Y;
    Gastroenterology; 2017 May; 152(6):1383-1394. PubMed ID: 28163062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct-Acting Antivirals Reduce the De Novo Development of Esophageal Varices in Patients with Hepatitis C Virus Related Liver Cirrhosis.
    Hsieh YY; Chen WM; Chang KC; Chang TS; Hung CH; Yang YH; Tung SY; Wei KL; Shen CH; Wu CS; Ding YJ; Hu JH; Huang YT; Lin MH; Lu CK; Lin YH; Lin MS
    Viruses; 2023 Jan; 15(1):. PubMed ID: 36680293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis.
    Lens S; Alvarado-Tapias E; Mariño Z; Londoño MC; LLop E; Martinez J; Fortea JI; Ibañez L; Ariza X; Baiges A; Gallego A; Bañares R; Puente A; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; Forns X; García-Pagán JC
    Gastroenterology; 2017 Nov; 153(5):1273-1283.e1. PubMed ID: 28734831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term outcome of chronic hepatitis C in a population-based cohort and impact of antiviral therapy: a propensity-adjusted analysis.
    Di Martino V; Crouzet J; Hillon P; Thévenot T; Minello A; Monnet E
    J Viral Hepat; 2011 Jul; 18(7):493-505. PubMed ID: 21692956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin.
    Shiffman ML; James AM; Long AG; Alexander PC
    Am J Gastroenterol; 2015 Aug; 110(8):1179-85. PubMed ID: 26215530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study.
    Bruno S; Zuin M; Crosignani A; Rossi S; Zadra F; Roffi L; Borzio M; Redaelli A; Chiesa A; Silini EM; Almasio PL; Maisonneuve P
    Am J Gastroenterol; 2009 May; 104(5):1147-58. PubMed ID: 19352340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DAA treatment for HCV reduce risk of hepatocellular carcinoma: a 10-years follow-up study based on Chinese patients with hepatitis C.
    Zhu X; Jia L; Yue M; Zhang A; Xia X; Yu R; Chen H; Huang P
    Sci Rep; 2024 Oct; 14(1):23760. PubMed ID: 39390065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.